Trial Profile
A Double-Blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Mar 2018
Price :
$35
*
At a glance
- Drugs Tilavonemab (Primary)
- Indications Progressive supranuclear palsy
- Focus Adverse reactions
- Sponsors C2N Diagnostics
- 24 Mar 2018 Results of analysis characterizing the pharmacokinetics of ABBV-8E12 in patients with PSP and evaluating factors influencing plasma exposures presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017.
- 08 Jun 2017 Results presented at the 21st International Congress of Parkinson's Disease and Movement Disorders.